Clinical Trial Update: Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 study assessing lorlatinib for newly diagnosed high-grade gliomas with ALK or ROS1 fusions; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma H3k27-altered
• Glioblastoma
• High-grade Glioma
• Infant-type Hemispheric Glioma
• Who Grade Iii Glioma
• Who Grade Iv Glioma

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma | EARLY_Phase 1 | Status: RECRUITING